P9-4 Polypharmacy as a prognostic factor in older patients with advanced NSCLC

Abstract

Background: With the recent development of immune checkpoint inhibitors (ICIs), the use of ICIs for managing postoperative recurrence of non-small cell lung cancer (NSCLC) is increasing. In this study, we retrospectively examined the postoperative recurrence cases of NSCLC where nivolumab was used for treatment and evaluated the prognostic factors.Methods: Patients who received nivolumab monotherapy for postoperative recurrence of NSCLC from March 2016 to September 2020 in our department were included in this study. Information on age, sex, performance status (PS) at the time of administration, histological type, recurrence type, presence/absence of adverse events, number of administrations, and outcomes was retrieved from the medical records and analyzed retrospectively. The survival was estimated using the Kaplan-Meier method, and comparisons between groups were performed using the log-rank method.